DLVR’s innovative technology is based on the synthesis and use of an HDL-mimetic phospholipid-based nanoparticle called HPPS (HDL-like Peptide-Phospholipid Scaffold).
DLVR Therapeutics Inc. is based in Toronto. Co-founded by University Health Network, the Ontario Institute for Cancer Research and MaRS Innovation, the Company is developing an innovative, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system. HPPS enhances cell targeting and bypasses endosomal degradation, two common problems which beset contemporary delivery systems. Mechanistically, HPPS appropriates HDL’s affinity for its natural ligand, Scavenger Receptor B1 (SR-B1) to preferentially target this receptor. Upregulated in many solid tumors such as breast, colorectal, pancreatic and ovarian, SR-B1 facilitates direct delivery of payload to the cytosol of tumor cells. The ultra-small HPPS particle is suitable for a variety of different RNAi payloads. The company’s development strategy is to collaborate with partners that have developed novel RNAi therapeutics that require an innovative delivery technology.